Stevenson, Matt D <br/><br/>
The cost-effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III.  [electronic resource] 

 -  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research   
 - 1100-5 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1524-4733 
<br/><br/><label>Standard No.: </label>10.1111/j.1524-4733.2009.00568.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antihypertensive Agents--economics<br/>Bosentan<br/>Child<br/>Confidence Intervals<br/>Connective Tissue Diseases--complications<br/>Cost-Benefit Analysis<br/>Disease Progression<br/>Epoprostenol--economics<br/>Female<br/>Health Care Costs<br/>Health Expenditures<br/>Humans<br/>Hypertension, Pulmonary--complications<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Models, Economic<br/>Palliative Care--economics<br/>Quality of Life<br/>Quality-Adjusted Life Years<br/>Sulfonamides--economics<br/>United Kingdom<br/>World Health Organization<br/>Young Adult